Table 2.
Patient characteristics.a
| Characteristic | CY/TBU (n=51) Cases | TBU/CY (n=271) Controls |
|---|---|---|
| Age, in years | 55 (30–65) | 50 (19–67) |
| Diagnosis | ||
| Acute myeloid leukemia | 20 (39%) | 143 (53%) |
| Myelodysplasia | 11 (22%) | 95 (35%) |
| Myelofibrosis | 20 (39%) | 33 (12%) |
| Donor | ||
| Related | 28 (55%) | 96 (35%) |
| Unrelated | 23 (45%) | 175 (65%) |
| HLA-matched | 21 | 98 |
| 1-HLA-allele-mismatched | 2 | 77 |
| Allograft source | ||
| G-PBMC | 51 (100%) | 223 (83%) |
| Bone marrow | 0 (0%) | 48 (17%) |
| CD34+ dose, in cells/kg recipient weight | 13.4 (6.8–28.5) | 9.1 (0.5–45.0) |
| Kahl disease riskb | ||
| Low/moderate | 30 (59%) | 196 (72%) |
| High | 21 (41%) | 75 (28%) |
a
Data presented as median (range) or number (%).
Abbreviations: CY, cyclophosphamide; TBU, targeted busulfan; HLA, human leukocyte antigen; G-PBMC, granulocyte colony stimulating factor-mobilized peripheral blood mononuclear cells; IV, intravenous.
b
Kahl disease risk measures risk of relapse after allogeneic hematopoietic cell transplantation [21].